Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Cencora (COR)

NYSE: COR · Medical Distribution · Conshohocken, PA

Our rating: Neutral

Neutral reaffirmed at $325.00, moderate conviction, August 10, 2026.

Breaks if: Turns Cautious if trailing twelve-month free cash flow falls below $2.5B at either of the next two quarterly filings — indicating the working-capital cushion is unwinding rather than persisting — or if full-year revenue growth decelerates to below 5% at the next annual report. Turns Positive if the next annual report shows free cash flow of $3.8B or more alongside revenue growth of at least 10%, indicating the specialty volume tailwind is compounding rather than plateauing.

Key figures

Market value$64.7B
Revenue, last 12 months$332.8B
Net income, last 12 months$2.6B
Free cash flow, last 12 months$4.1B
Price to earnings24.7×
Free cash flow yield6.3%
Dividend yield0.7%
Operating margin0.9%
Return on equity104.3%
Beta to the S&P 5000.03
Volatility, annualized25.9%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
June 30, 2026$84.8B5.1%$3.94$2.4B
March 31, 2026$78.4B3.8%$8.40$1.2B
December 31, 2025$85.9B5.5%$2.87−$2.4B
September 30, 2025$83.7B5.9%$-1.74$2.9B
June 30, 2025$80.7B8.7%$3.52−$74M
March 31, 2025$75.5B10.3%$3.68$3.2B
December 31, 2024$81.5B12.8%$2.50−$2.8B
September 30, 2024$79.1B14.7%$0.04$818M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

14 ledger entries and 67 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.